<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938339</url>
  </required_header>
  <id_info>
    <org_study_id>PETMR-Prostate</org_study_id>
    <nct_id>NCT01938339</nct_id>
  </id_info>
  <brief_title>Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer</brief_title>
  <official_title>Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To development of clinical assessment technique using multi-radiotracer positron emission&#xD;
      tomography/magnetic resonance (PET/MR) in prostate cancer&#xD;
&#xD;
        -  to establish the optimal imaging technique of PET/MR using multiple radioactive tracers&#xD;
           for prostate cancer&#xD;
&#xD;
        -  to establish the imaging biomarker using PET/MR for clinical assessment of prostate&#xD;
           cancer and early detection of recurrent prostate cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To establish the optimal imaging technique of PET/MR using multiple radioactive tracers for&#xD;
      prostate cancer&#xD;
&#xD;
        -  Recruiting 30 patients with prostate cancer ahead to radical prostatectomy&#xD;
&#xD;
        -  PET/MR using 18F-choline with dedicated prostate MRI in all patients&#xD;
&#xD;
        -  PET/MR using 18fluoride(F)-fluorodeoxyglucose(FDG)in all patients after 2-7 days&#xD;
&#xD;
        -  PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR&#xD;
&#xD;
        -  outcome assessment: comparison of scan time, image quality, tumor detection rate,&#xD;
           standardized uptake values of lesions&#xD;
&#xD;
        -  establishing optimal imaging technique for prostate PET/MR&#xD;
&#xD;
      To establish the imaging biomarker using PET/MR for clinical assessment of prostate cancer&#xD;
&#xD;
        -  comparison of findings on PET/MR, MRI and PET/CT with pathological mapping after radical&#xD;
           prostatectomy&#xD;
&#xD;
        -  outcome assessment: accuracy of PET/MR for localization and staging of prostate cancer&#xD;
           compared with MRI only and PET/CT only&#xD;
&#xD;
      To establish the imaging biomarker using PET/MR for early detection of recurrent prostate&#xD;
      cancer&#xD;
&#xD;
        -  Recruiting 15 patients with recurrent prostate cancer treated by surgery, hormone, or&#xD;
           radiation therapy&#xD;
&#xD;
        -  Recruiting 15 patients with treated prostate cancer without recurrence&#xD;
&#xD;
        -  PET/MR using 18F-choline with dedicated prostate MRI in all patients&#xD;
&#xD;
        -  PET/MR using 18F-FDG in all patients after 2-7 days&#xD;
&#xD;
        -  PET/CT using 18F-FDG in all patient immediate after 18F-FDG PET/MR&#xD;
&#xD;
        -  comparison of findings on PET/MR, MRI, and PET/CT with clinical data in two patient&#xD;
           groups with or without recurrent prostate cancer&#xD;
&#xD;
        -  outcome assessment: accuracy of PET/MR for early detection and localization of recurrent&#xD;
           prostate cancer compared with MRI only and PET/CT only&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>accuracy of PET/MR predicting localization and staging of prostate cancer</measure>
    <time_frame>1 week after radical prostatectomy</time_frame>
    <description>analysis of accuracy of PET/MR predicting localization and staging of prostate cancer by comparison of PET/MR findings with pathological mapping images after radical prostatectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>accuracy of early detection and localization of recurrent prostate cancer</measure>
    <time_frame>1 week after PET/MR imaging</time_frame>
    <description>accuracy of PET/MR for early detection and localization of recurrence by comparison of PET/MR findings with clinical data in two groups of patients with or without recurrent prostate cancer</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer Recurrent</condition>
  <condition>Stage II Prostate Carcinoma</condition>
  <condition>Stage III Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>PET/MR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/MR</intervention_name>
    <description>Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer</description>
    <arm_group_label>PET/MR</arm_group_label>
    <other_name>Biograph mMR, Siemens Healthcare</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with prostate cancer before treatment&#xD;
&#xD;
          -  patient with prostate cancer treated&#xD;
&#xD;
          -  patient with prostate cancer recurrent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with contraindication for MRI&#xD;
&#xD;
          -  Patient with severe renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Yeon Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong Yeon Cho, MD</last_name>
    <phone>82-2-2072-3074</phone>
    <email>radjycho@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang Youn Kim, MD</last_name>
    <phone>82-2-2072-3321</phone>
    <email>iwishluv@empas.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyeon Jin Kim, RN</last_name>
      <phone>82-10-9944-2569</phone>
      <email>onara53@naver.com</email>
    </contact>
    <investigator>
      <last_name>Jin Chul Paeng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gi Jeong Cheon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheol Kwak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>September 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>MRI</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

